<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39226490</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J Clin Oncol</ISOAbbreviation></Journal><ArticleTitle>Exposure-Response-Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs.</ArticleTitle><Pagination><StartPage>JCO2400349</StartPage><MedlinePgn>JCO2400349</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.24.00349</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The advent of new therapeutic modalities highlighted deficiencies in the traditional maximum tolerated dose approach for oncology drug dose selection and prompted the Food and Drug Administration (FDA)'s <i>Project Optimus</i> initiative, which suggests that sponsors take a holistic approach, including efficacy, safety, and pharmacokinetic (PK) and pharmacodynamic data, in conjunction with integrated exposure-response (ER) analyses. However, this method comes with an inherent challenge of the collation of the multisource data. To address this issue, an ER-based clinical utility score (CUS) framework, combining benefit and risk into a single measurement, was developed.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Model-predicted outcomes for each clinically relevant end point, informed by ER modeling, are converted to a CUS using a user-defined utility function. Thereafter, individual CUS is integrated into a single score with user-defined weighting for each end point. The user-defined weighting feature allows the user to incorporate expert knowledge/understanding into weighing the product's benefit versus risk profile.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">To validate the framework, data were leveraged from over 50 oncology programs from 2019 to 2023 on the basis of FDA new drug application/biologics license application review packages and/or related literature studies. Five representative cases were selected for in-depth evaluation. Results showed that the optimal benefit-risk ratio (highest CUS) was consistently observed at PK exposures synonymous with recommended doses. A recurring theme across cases was a greater emphasis on safety over efficacy in oncology drug dose determination.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The ER-based CUS framework offers a strategic tool to navigate the complexities of dose selection in oncology programs. It serves as a pillar to the importance of integrative data analysis, aligning with the vision of <i>Project Optimus</i>, and demonstrates its potential in guiding dose optimization by balancing therapeutic benefits against risk.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yiming</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5428-9418</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology, Pharmacometrics &amp; Bioanalysis, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Shuyu</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5208-4272</Identifier><AffiliationInfo><Affiliation>Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology, Pharmacometrics &amp; Bioanalysis, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Global Drug Development, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maciag</LastName><ForeName>Paulo</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1172-9772</Identifier><AffiliationInfo><Affiliation>Global Drug Development, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8804-4897</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology, Pharmacometrics &amp; Bioanalysis, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bello</LastName><ForeName>Akintunde</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology, Pharmacometrics &amp; Bioanalysis, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0002-9079-0503</Identifier><AffiliationInfo><Affiliation>Clinical Pharmacology, Pharmacometrics &amp; Bioanalysis, Bristol Myers Squibb, Princeton, NJ.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2024 Sep 11:JCO2401372. doi: 10.1200/JCO-24-01372</RefSource><PMID Version="1">39259929</PMID></CommentsCorrections></CommentsCorrectionsList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>18</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39226490</ArticleId><ArticleId IdType="doi">10.1200/JCO.24.00349</ArticleId></ArticleIdList></PubmedData></PubmedArticle>